New CEO named for Durham-based Bioventus
DURHAM – A new chief executive has been named to lead Bioventus, the Durham-based bone treatment company that was spun out from a division of the London-based multinational medical device company Smith & Nephew through a deal with venture capital firm Essex Woodlands.
Anthony P. Bihl III, 57, will join the company Dec. 2 as CEO, according to a news release. He takes the role vacated by Mark Augusti, who resigned in August.
He previously served as CEO and president of American Medical Systems, a urology medical devices provider, according to the release.
Before working at AMS, he was CEO of Siemens Medical Solutions Diagnostics, a division of Siemens AG focused on in vitro diagnostics.
He also served as president of the diagnostics division of Bayer Healthcare LLC, and as executive vice president for Bayer Healthcare LLC. The division was acquired by Siemens for $5.4 billion.
Bioventus employs about 600 people, according to a spokesman. It has about 75 workers in offices on Emperor Boulevard in Durham, about 125 in Memphis, Tenn., and about 275 working in field sales. The remainder is outside the country.
Its existing products include an ultrasound bone healing system, a joint therapy for osteoarthritis, and portable ultrasound equipment for orthopedic clinics.